Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

A disintegrin and metalloproteinase with thrombospondin motifs 2 cleaves and inactivates Reelin in the postnatal cerebral cortex and hippocampus, but not in the cerebellum.

Yamakage Y, Kato M, Hongo A, Ogino H, Ishii K, Ishizuka T, Kamei T, Tsuiji H, Miyamoto T, Oishi H, Kohno T, Hattori M.

Mol Cell Neurosci. 2019 Sep 3;100:103401. doi: 10.1016/j.mcn.2019.103401. [Epub ahead of print]

PMID:
31491533
2.

Upstream Position of Proline Defines Peptide-HLA Class I Repertoire Formation and CD8+ T Cell Responses.

Hongo A, Kanaseki T, Tokita S, Kochin V, Miyamoto S, Hashino Y, Codd A, Kawai N, Nakatsugawa M, Hirohashi Y, Sato N, Torigoe T.

J Immunol. 2019 May 15;202(10):2849-2855. doi: 10.4049/jimmunol.1900029. Epub 2019 Apr 1.

PMID:
30936292
3.

Association between chemical components of PM2.5 and children's primary care night-time visits due to asthma attacks: A case-crossover study.

Yamazaki S, Shima M, Yoda Y, Kurosaka F, Isokawa T, Shimizu S, Ogawa T, Kamiyoshi N, Terada K, Nishikawa J, Hanaoka K, Yamada T, Matsuura S, Hongo A, Yamamoto I.

Allergol Int. 2019 Jul;68(3):329-334. doi: 10.1016/j.alit.2019.01.001. Epub 2019 Feb 7.

4.

'Head-to-Head' mRNA display for the translation of multi-copied proteins with a free C-terminus.

Sharma K, Hongo A, Nishigaki K, Takamura Y, Biyani M.

Anal Biochem. 2018 Sep 15;557:77-83. doi: 10.1016/j.ab.2018.07.015. Epub 2018 Jul 19.

PMID:
30031739
5.

Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).

Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T.

Int J Clin Oncol. 2019 Jan;24(1):103-114. doi: 10.1007/s10147-018-1319-y. Epub 2018 Jul 20.

6.

The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.

Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, Ishitani K, Hata F, Takemasa I, Miyazaki A, Hiratsuka H, Sato N, Torigoe T.

Cancer Immunol Res. 2018 Mar;6(3):358-369. doi: 10.1158/2326-6066.CIR-17-0518. Epub 2018 Jan 25.

7.

Development of Cell Analysis Software for Cultivated Corneal Endothelial Cells.

Okumura N, Ishida N, Kakutani K, Hongo A, Hiwa S, Hiroyasu T, Koizumi N.

Cornea. 2017 Nov;36(11):1387-1394. doi: 10.1097/ICO.0000000000001317.

PMID:
28834811
8.

The Effect of a p38 Mitogen-Activated Protein Kinase Inhibitor on Cellular Senescence of Cultivated Human Corneal Endothelial Cells.

Hongo A, Okumura N, Nakahara M, Kay EP, Koizumi N.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3325-3334. doi: 10.1167/iovs.16-21170.

PMID:
28672399
9.

Accelerated Lymph Flow in Early-Stage Secondary Lymphedema Detected by Indocyanine Green Fluorescence Lymphography.

Shinaoka A, Koshimune S, Yamada K, Matsumoto K, Honda M, Miyake M, Furuichi H, Hongo A, Kimata Y.

J Reconstr Microsurg. 2017 Oct;33(8):596-602. doi: 10.1055/s-0037-1603740. Epub 2017 Jun 19. No abstract available.

PMID:
28628934
10.

Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Shionoya Y, Kanaseki T, Miyamoto S, Tokita S, Hongo A, Kikuchi Y, Kochin V, Watanabe K, Horibe R, Saijo H, Tsukahara T, Hirohashi Y, Takahashi H, Sato N, Torigoe T.

Oncoimmunology. 2017 Jan 3;6(2):e1274476. doi: 10.1080/2162402X.2016.1274476. eCollection 2017.

11.

A radioisotope-nondependent high-sensitivity method for measuring the activity of glioblastoma-related O(6)-methylguanine DNA methyltransferase.

Hongo A, Gu R, Suzuki M, Nemoto N, Nishigaki K.

Anal Biochem. 2015 Jul 1;480:82-4. doi: 10.1016/j.ab.2014.08.012. Epub 2014 Aug 28.

PMID:
25173514
12.

Three cases of struma ovarii underwent laparoscopic surgery with definite preoperative diagnosis.

Nurliza Binti Md Nor, Kusumoto T, Inoue S, Nakamura K, Seki N, Hongo A, Kodama J, Hiramatsu Y.

Acta Med Okayama. 2013;67(3):191-5.

13.

Stage IB1 cervical cancer patients with an MRI-measured tumor size < or = 2 cm might be candidates for less-radical surgery.

Kodama J, Fukushima C, Kusumoto T, Nakamura K, Seki N, Hongo A, Hiramatsu Y.

Eur J Gynaecol Oncol. 2013;34(1):39-41.

PMID:
23589998
14.

Elevated preoperative plasma D-dimer levels and the incidence of venous thromboembolism in Japanese females with gynecological cancer.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2013 Jan;5(1):299-304. Epub 2012 Oct 15.

15.

Changes in soluble fibrin levels during the perioperative period of gynecologic cancer surgery.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2012 Nov;4(5):1122-1124. Epub 2012 Aug 31.

16.

Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial).

Nasu K, Satoh T, Nishio S, Nagai Y, Ito K, Otsuki T, Hongo A, Hirashima Y, Ogura T, Shimada M.

Gynecol Oncol. 2013 Feb;128(2):198-203. doi: 10.1016/j.ygyno.2012.11.001. Epub 2012 Nov 8.

PMID:
23142074
17.

The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer.

Nakamura K, Joja I, Fukushima C, Haruma T, Hayashi C, Kusumoto T, Seki N, Hongo A, Hiramatsu Y.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):52-60. doi: 10.1007/s00259-012-2240-7. Epub 2012 Sep 12.

PMID:
22968401
18.

Short communication: effect of difructose anhydride III on serum immunoglobulin G concentration in newborn calves.

Sato T, Hanada M, Ohtani M, Nakai T, Teramura M, Sadoya H, Takahashi T, Hongo A.

J Dairy Sci. 2012 Sep;95(9):5336-5339. doi: 10.3168/jds.2011-4989.

19.

The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker for disease recurrence.

Nakamura K, Joja I, Nagasaka T, Fukushima C, Kusumoto T, Seki N, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2012 Dec;127(3):478-83. doi: 10.1016/j.ygyno.2012.07.123. Epub 2012 Aug 11.

PMID:
22892362
20.

Role of emmprin in endometrial cancer.

Nakamura K, Kodama J, Hongo A, Hiramatsu Y.

BMC Cancer. 2012 May 28;12:191. doi: 10.1186/1471-2407-12-191.

21.

Anti-angiogenesis effect of 3'-sulfoquinovosyl-1'-monoacylglycerol via upregulation of thrombospondin 1.

Matsuki K, Tanabe A, Hongo A, Sugawara F, Sakaguchi K, Takahashi N, Sato N, Sahara H.

Cancer Sci. 2012 Aug;103(8):1546-52. doi: 10.1111/j.1349-7006.2012.02333.x. Epub 2012 Jun 20.

22.

[I. Uterine cervical neoplasms 2. Strategy for treatment of adenocarcinoma in situ of uterine cervix and the role of chemotherapy ].

Hongo A.

Gan To Kagaku Ryoho. 2012 Feb;39(2):184-9. Review. Japanese. No abstract available.

PMID:
22545284
23.

Antitumor effects of novel shorter truncated insulin-like growth factor I receptors.

Ojima Y, Hongo A, Liu Y, Zhu L, Kusumoto T, Nakamura K, Seki N, Hiramatsu Y.

Cancer Biol Ther. 2012 May;13(7):559-66. doi: 10.4161/cbt.19609. Epub 2012 May 1.

PMID:
22406993
25.

AgI-coated silver-clad stainless steel hollow waveguides for infrared lightwave transmission and their applications.

Hongo A, Sato S, Hattori A, Iwai K, Takaku H, Miyagi M.

Appl Opt. 2012 Jan 1;51(1):1-7. doi: 10.1364/AO.51.000001.

PMID:
22270406
26.

Effects of N-[N-(3, 5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) on cell proliferation and apoptosis in Ishikawa endometrial cancer cells.

Mori M, Miyamoto T, Yakushiji H, Ohno S, Miyake Y, Sakaguchi T, Hattori M, Hongo A, Nakaizumi A, Ueda M, Ohno E.

Hum Cell. 2012 Mar;25(1):9-15. doi: 10.1007/s13577-011-0038-8. Epub 2011 Dec 22.

PMID:
22189483
27.

Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Nakamura K, Joja I, Kodama J, Hongo A, Hiramatsu Y.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):283-90. doi: 10.1007/s00259-011-1978-7. Epub 2011 Nov 10.

PMID:
22072286
28.

Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.

Nakamura K, Imafuku N, Nishida T, Niwa I, Joja I, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2012 Feb;124(2):335-9. doi: 10.1016/j.ygyno.2011.10.014. Epub 2011 Oct 18.

PMID:
22008707
29.

The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2011 Oct;123(1):82-7. doi: 10.1016/j.ygyno.2011.06.026. Epub 2011 Jul 20.

PMID:
21764107
30.

Factors associated with parametrial involvement in stage IB1 cervical cancer and identification of patients suitable for less radical surgery.

Kodama J, Kusumoto T, Nakamura K, Seki N, Hongo A, Hiramatsu Y.

Gynecol Oncol. 2011 Sep;122(3):491-4. doi: 10.1016/j.ygyno.2011.05.038. Epub 2011 Jun 24.

PMID:
21703671
31.

Fat accumulation in adipose tissues as a risk factor for the development of endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Oncol Rep. 2011 Jul;26(1):65-71. doi: 10.3892/or.2011.1259. Epub 2011 Apr 13.

PMID:
21491090
32.

Complications and obstetric outcomes after laser conization during pregnancy.

Seki N, Kodama J, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Eur J Gynaecol Oncol. 2010;31(4):399-401.

PMID:
20882881
33.

The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Int J Cancer. 2011 Jun 1;128(11):2613-24. doi: 10.1002/ijc.25606. Epub 2010 Oct 4.

34.

Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2010 Sep;37(3):605-14.

PMID:
20664929
35.

The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix.

Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y.

Gynecol Oncol. 2010 Oct;119(1):81-6. doi: 10.1016/j.ygyno.2010.04.020. Epub 2010 Jun 26.

PMID:
20580064
36.

A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.

Hongo A, Kusumoto T, Nakamura K, Seki N, Kodama J, Hiramatsu Y.

Int J Clin Oncol. 2010 Oct;15(5):476-83. doi: 10.1007/s10147-010-0099-9. Epub 2010 Jun 8.

PMID:
20526888
37.

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis.

Kodama J, Sasaki A, Masahiro S, Seki N, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2010 May;1(3):511-513. Epub 2010 May 1.

38.

Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer.

Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Rep. 2010 Apr;23(4):917-25.

PMID:
20204274
39.

α-fetoprotein-producing endometrial adenocarcinoma without an obvious hepatoid component.

Kodama J, Seki N, Yanai H, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2010 Mar;1(2):243-245. Epub 2010 Mar 1.

40.

The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer.

Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y.

Int J Gynecol Cancer. 2010 Jan;20(1):110-5. doi: 10.1111/IGC.0b013e3181c3a288.

PMID:
20130510
41.

D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer.

Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Ann Oncol. 2010 Aug;21(8):1651-6. doi: 10.1093/annonc/mdq012. Epub 2010 Feb 3.

PMID:
20129998
42.

Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy.

Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

J Surg Oncol. 2010 Apr 1;101(5):413-7. doi: 10.1002/jso.21499.

PMID:
20127891
43.

Fabrication and transmission characteristics of infrared hollow fiber based on silver-clad stainless steel pipes.

Iwai K, Hongo A, Takaku H, Miyagi M, Ishiyama J, Wu XX, Shi YW, Matsuura Y.

Appl Opt. 2009 Nov 10;48(32):6207-12. doi: 10.1364/AO.48.006207.

PMID:
19904318
44.

The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2009 Aug;35(2):239-48.

PMID:
19578736
45.

Expression of matriptase and clinical outcome of human endometrial cancer.

Nakamura K, Hongo A, Kodama J, Abarzua F, Nasu Y, Kumon H, Hiramatsu Y.

Anticancer Res. 2009 May;29(5):1685-90.

46.

Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.

Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2009 Feb;34(2):345-53.

PMID:
19148468
47.

Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens.

Kuramoto H, Hongo A, Liu YX, Ojima Y, Nakamura K, Seki N, Kodama J, Hiramatsu Y.

Acta Med Okayama. 2008 Aug;62(4):251-9.

48.

Hepsin inhibits the cell growth of endometrial cancer.

Nakamura K, Takamoto N, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Mol Med. 2008 Sep;22(3):389-97.

PMID:
18698500
49.

Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Ann Oncol. 2009 Jan;20(1):63-70. doi: 10.1093/annonc/mdn556. Epub 2008 Aug 9.

PMID:
18689863
50.

Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.

Nakamura K, Takamoto N, Hongo A, Kodama J, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y.

Oncol Rep. 2008 May;19(5):1085-91.

PMID:
18425362

Supplemental Content

Support Center